Anakinra treatment for systemic onset juvenile idiopathic arthritis in Libyan Children

Abstract :

Systemic onset juvenile idiopathic arthritis (SoJIA) is a rare inflammatory disorder. It is the severest form of juvenile idiopathic arthritis, and complications occur most commonly in this type. Non-responsiveness to standard therapy with corticosteroids and disease-modifying antirheumatic drugs is not uncommon. Interleukin-1 beta (Il-1β) has been shown to be a main contributor to the pathogenesis of SoJIA. Anakinra, a recombinant Il-1β receptor antagonist, was shown to be effective in small cohorts of therapy-resistant adult and pediatric still's patients. This study aimed to evaluate the real-world efficacy, steroid-sparing effect, and safety profile of anakinra in patients with SoJIA at a tertiary care center in Libya. A retrospective case series was conducted on patients with SoJIA treated with anakinra at the Tripoli Children's Hospital between 2010 and 2017. Data on demographic characteristics, disease activity, corticosteroid dosage, concomitant medications, and adverse events were collected at baseline and at 1-, 3-, 6-, and 12-month post-treatment. 13 patients were treated with anakinra with a mean age of 9.4±4.6 years at anakinra initiation and a female-to-male ratio of 2: 1. All patients were on corticosteroids and 92.3% on methotrexate at treatment initiation. The proportion of patients achieving inactive disease (Jadas 10=0) increased over time. A marked steroid-sparing effect was observed: the number of patients requiring high-dose steroids (>0.5 mg/kg/day) decreased from 100% at baseline to 7.6% at 12 months, and 53.8% successfully discontinued corticosteroids entirely. All patients experienced injection site reaction, and macrophage activation syndrome occurred in 15.4% as a side effect after treatment initiation. But no severe infections or fatalities occurred. Reasons for discontinuation included remission (46.1%), drug unavailability (23.0%), inefficacy (15.3%), and side effects (15.3%). Anakinra demonstrated significant efficacy in inducing rapid disease control and reducing corticosteroid dependence in patients with refractory SoJIA, with a manageable safety profile.

References

1. Lequerré T, Quartier P, Rosellini D, Alaoui F, Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: Preliminary experience in France. Annals of the Rheumatic Diseases. 2008; 67(3): 302-308. doi: 10.1136/Ard. 2007.076034
2. Hedrich CM, Bruck N, Fiebig B, Ghar M. Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology International. 2012; 32(11): 3525-3530. doi: 10.1007/S00296-011-2249-4
3. Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JMP, Cohen N, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: A systematic review and meta-analysis of randomized trials. Rheumatology. 2015; 55(4): 669-679. doi: 10.1093/Rheumatology/Kev382
4. Thatayatikom A, Modica R, De Leucio A. Juvenile Idiopathic Arthritis. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 32119492.
5. Wagner N, Zepp F. Pädiatrische Rheumatologie. Pediatric Rheumatology. 2012; 160(3): 215-216. doi: 10.1007/ S00112-011-2544-X
6. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum M A, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series. Arthritis and Rheumatism. 2011; 63(2): 545-555. doi: 10.1002/Art.30128
7. Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatric Clinics of North America. 2018; 65(4): 691-709. doi: 10.1016/J.Pcl.2018.04.005
8. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmunity Reviews. 2016; 15(9): 931-934. doi: 10.1016 /J.Autrev.2016.07.004
9. Kumar S. Systemic juvenile idiopathic arthritis: Diagnosis and management. Indian Journal of Pediatrics. 2016; 83(4): 322-327. doi: 10.1007/S12098-016-2060-Z
10. Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: A review of clinical presentation and treatment. International Journal of Inflammation. 2012; 2012: 271569. doi: 10.1155/2012/271569
11. Saccomanno B, Tibaldi J, Minoia F, Bagnasco F, Pistorio A, Guariento A, et al. Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis. The Journal of Rheumatology. 2019; 46(4): 416-421. doi: 10.3899 /Jrheum. 180331
12. Sawhney S, Agarwal M. Outcome measures in pediatric rheumatology. Indian Journal of Pediatrics. 2010; 77(10): 1183-1189. doi: 10.1007/S12098-010-0208-9
13. Sherry DD, Kredich DW. Transient thrombocytopenia in systemic onset juvenile rheumatoid arthritis. Pediatrics. 1985; 76(4): 600-603. PMID: 4047803.
14. Miller JJ 3rd, Hsu YP, Moss R, Kelomaa-Sulonen K, Osborne CL, Olds-Arroyo L. The immunologic and clinical associations of the split products of C3 in plasma in juvenile rheumatoid arthritis. Arthritis Rheumatism. 1979; 22(5): 502-507. doi: 10.1002/art.1780220510.
15. Ewer AK, Darbyshire PJ, Southwood TR. Systemic-onset juvenile chronic arthritis and bone marrow hypoplasia. British Journal of Rheumatology. 1993; 32(1): 78-80. doi: 10.1093/rheumatology/32.1.78
16. Rubin RN, Walker BK, Ballas SK, Travis SF. Erythroid aplasia in juvenile rheumatoid arthritis. American Journal of Diseases of Children. 1978; 132(8): 760-762. doi: 10.1001/archpedi.1978.02120330032007
17. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS Trial). Annals of the Rheumatic Diseases. 2011; 70(5): 747-754. doi: 10.1136/ard. 2010.134254
18. Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin‐1 treatment distinguishes two subsets of patients with systemic‐onset juvenile idiopathic arthritis. Arthritis and Rheumatism. 2008; 58(5): 1505-1515. doi: 10.1002/art.23437
19. Pardeo M, Marafon DP, Insalaco A, Bracaglia C, Nicolai R, Messia V, et al. Anakinra in systemic juvenile idiopathic arthritis: A single-center experience. The Journal of Rheumatology. 2015; 42(8): 1523-1527. doi: 10.3899/jrheum. 141567
20. Vastert SJ, De Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of IRST‐line treatment with recombinant interleukin‐1 receptor antagonist in steroid‐naive patients with new‐onset systemic juvenile idiopathic arthritis: Results of A prospective cohort study. Arthritis and Rheumatology. 2014; 66(4): 1034-1043. doi: 10.1002/art.38296
21. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (Anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: Preliminary experience in France. Annals of the Rheumatic Diseases. 2008; 67(3): 302-308. doi: 10.1136/ard. 2007.076034
22. Mcerlane F, Beresford Mw, Baildam EM, Thomson W, Hyrich Kl. Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. Rheumatology. 2013; 52(11): 1941-1951. doi: 10.1093/ Rheumatology/Ket150
23. Filocamo G, Consolaro A, Solari N, Palmisani E, Dalprà S, Suffia C, et al. Recent advances in quantitative assessment of juvenile idiopathic arthritis. Annals of Pediatric Rheumatology. 2012; 1(2): 84-96. doi: 10.5455/ Apr.032920121140
24. Ravelli A. The JADAS: A simple and reliable tool for the measurement of disease activity in juvenile idiopathic arthritis. Annals of Pediatric Rheumatology. 2014; 3: 1-3. doi: 10.5455/Apr.031720141923
25. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis and Rheumatism. 2009; 61(5): 658-666. doi: 10.1002/Art.24516
26. Wallace CA, Ruperto N, Giannini E. Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. The Journal of Rheumatology. 2004; 31(11): 2290-2294. PMID: 15517647.
27. Woo P. Systemic juvenile idiopathic arthritis: Diagnosis, management, and outcome. Nature Clinical Practice Rheumatology. 2006; 2(1): 28-34. doi: 10.1038/ncprheum0084
28. Ruperto N, Martini A. Current and future perspectives in the management of juvenile idiopathic arthritis. The Lancet. Child and Adolescent Health. 2018; 2(5): 360-370. doi: 10.1016/S2352-4642(18)30034-8
29. Ravelli A, Martini A. Juvenile Idiopathic Arthritis. The Lancet. 2007; 369(9563): 767-778. doi: 10.1016/S0140-6736 (07)60363-8

Citation :

Hashad SS, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis in Libyan Children. Mediterr J Pharm Pharm Sci. 2025; 5(4): 38-46. [Article number: 229]. https://doi.org/10.5281/zenodo.17553885